Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by18F-fluoride PET: A prospective study

Journal of Nuclear Medicine

Volumn 50, Issue 11, 2009, Pages 1808-1814

  Uchida, Kenzo ^a   Nakajima, Hideaki ^a   Miyazaki, Tsuyoshi ^a   Yayama, Takafumi ^a   Kawahara, Hideo ^a   Kobayashi, Shigeru ^a   Tsuchida, Tatsuro ^a   Okazawa, Hidehiko ^a   Fujibayashi, Yasuhisa ^a   Baba, Hisatoshi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

18F fluoride positron emission tomography (PET); Alendronate; Bone metabolism; Glucocorticoid; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; FLUORINE 18; GLUCOCORTICOID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASTHMA; BEHCET DISEASE; BONE DENSITY; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DERMATOMYOSITIS; DRUG MONITORING; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; LYMPHOMA; MULTIPLE SCLEROSIS; OSTEOPENIA; PEMPHIGOID; PEMPHIGUS; POLYMYOSITIS; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; URINE LEVEL;

AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; FEMALE; FLUORIDES; FLUORINE RADIOISOTOPES; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; OSTEOPOROSIS; POSITRON-EMISSION TOMOGRAPHY; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 70350708171     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.062570     Document Type: Article

References (40)

1. Klein RG, Arnaud SB, Gallangher JC, DeLuca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisonism: role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest. 1977;60:253-259.
2. Rubin MR, Bilezikian JP. Clinical review 151: the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis - a re-examination of the evidence. J Clin Endocrinol Metab. 2002;87:4033-4041.
3. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73-81.
4. Michel BA, Bloch DA, Wolfe F, Fries JF. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol. 1993;20:1666-1669. (Pubitemid 24017566)
5. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis. 1986;45:852-857. (Pubitemid 16007110)
6. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000. (Pubitemid 30350061)
7. Adachi JD, Olszynski WP, Hanley DA, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000;29:228-251.
8. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44: 1496-1503.
9. Bone and Tooth Society, National Osteoporosis Society, Royal College of Physicians. Glucocorticoid-Induced Osteoporosis: Guidelines for Prevention and Treatment. London, U.K.: Royal College of Physicians; 2002.
10. Nawata H, Soen S, Takayanagi R, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab. 2005;23:105-109. (Pubitemid 40591032)
11. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202-211.
12. Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res. 2003;18:919-924. (Pubitemid 37294977)
13. de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355:675-684.
14. 18F-fluoride for bone imaging. Semin Nucl Med. 1972;2:31-37.
15. Ishiguro K, Nakagaki H, Tsuboi S, et al. Distribution of fluoride in cortical bone of human rib. Calcif Tissue Int. 1993;52:278-282. (Pubitemid 23097159)
16. Narita N, Kato K, Nakagaki H, et al. Distribution of fluoride concentration in the rat's bone. Calcif Tissue Int. 1990;46:200-204. (Pubitemid 20084077)
17. Reeve J, Arlot M, Wootton R, et al. Skeletal blood flow, iliac histomorphometry, and strontium kinetics in osteoporosis: a relationship between blood flow and corrected apposition rate. J Clin Endocrinol Metab. 1988;66:1124-1131. (Pubitemid 18145500)
18. Hawkins RA, Choi Y, Huang SC, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33:633-642.
19. 18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab. 1993;77:949-955.
20. Piert M, Zittel TT, Becker GA, et al. Assessment of porcine bone metabolism by dynamic. J Nucl Med. 2001;42:1091-1100.
21. Frost ML, Fogelman I, Blake GM, Marsden PK, Cook G Jr. Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis. J Bone Miner Res. 2004;19:1797-1804. (Pubitemid 41103430)
22. 18F- fluoride positron emission tomography. J Bone Miner Res. 2002;17:854-859.
23. Installe J, Nzeusseu A, Bol A, et al. 18F-fluoride PET for monitoring therapeutic response in Paget's disease of bone. J Nucl Med. 2005;46:1650-1658. (Pubitemid 46211589)
24. 18F]fluoride PET indicates reduced bone formation in severe glucocorticoid-induced osteoporosis. Nuklearmedizin. 1998;37:76-79.
25. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
26. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic disease. Arthritis Rheum. 1985;28:361-368. (Pubitemid 15075486)
27. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-787.
28. Conti A, Sartorio A, Ferrero S, Ferrario S, Ambrosi B. Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy. J Endocrinol Invest. 1996;19:127-130. (Pubitemid 26107183)
29. Kollerup G, Hansen M, Horslev-Petersen K. Urinary hydrooxypyridinium cross-links of collagen in rheumatoid arthritis: relation to disease activity and effects of methylprednisolone. Br J Rheumatol. 1994;33:816-820. (Pubitemid 24283218)
30. Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res. 2005;20:464-470. (Pubitemid 40293495)
31. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003;9:2643-2658. (Pubitemid 37456015)
32. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339:292-299.
33. Balena R, Toolan BC, Shea M, et al. The effect of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 1993; 92:2577-2586. (Pubitemid 24006520)
34. 18F-fluoride PET scans. J Nucl Med. 2004;45:1493-1500.
35. 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turnover. J Clin Densitom. 2007;10:46-54.
36. Peters AM, Myers MJ. Body fluids, electrolytes and bone. In: Peters AM, Myers MJ, eds. Physiological Measurements with Radionuclides in Clinical Practice. New York, NY: Oxford University Press; 1998:262-278.
37. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998;83:396-402. (Pubitemid 28496512)
38. 18F-fluoride positron emission tomography. J Bone Miner Res. 2003;18: 2215-2222.
39. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20:962-970. (Pubitemid 40712820)
40. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab. 2000;85: 3537-3540.